Literature DB >> 31217240

Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins.

Nitesh Mishra1, Muzamil Ashraf Makhdoomi1,2, Shaifali Sharma1, Sanjeev Kumar1, Ayushman Dobhal1, Deepshikha Kumar1, Himanshi Chawla1, Ravinder Singh3, Uma Kanga4, Bimal Kumar Das3, Rakesh Lodha5, Sushil K Kabra5, Kalpana Luthra6.   

Abstract

Broad and potent neutralizing antibodies (bnAbs) with multiple epitope specificities evolve in HIV-1-infected children. Herein, we studied two antiretroviral-naive chronically HIV-1 clade C-infected monozygotic pediatric twins, AIIMS_329 and AIIMS_330, with potent plasma bnAbs. Elite plasma neutralizing activity was observed since the initial sampling at 78 months of age in AIIMS_330 and persisted throughout, while in AIIMS_329 it was seen at 90 months of age, after which the potency decreased over time. We evaluated potential viral characteristics associated with the varied immune profiles by generating single genome-amplified pseudoviruses. The AIIMS_329 viruses generated from the 90-month time point were neutralization sensitive to bnAbs and contemporaneous plasma antibodies, while viruses from the 112-month and 117-month time points were resistant to most bnAbs and contemporaneous plasma. AIIMS_329 viruses developed resistance to plasma neutralizing antibodies (nAbs) plausibly by N160 glycan loss and V1 and V4 loop lengthening. The viruses generated from AIIMS_330 (at 90 and 117 months) showed varied susceptibility to bnAbs and autologous contemporaneous plasma antibodies, while the viruses of the 112-month time point, at which the plasma nAb specificities mapped to the V2 glycan, V3 glycan, and CD4 binding site (CD4bs), were resistant to contemporaneous plasma antibodies as well as to most bnAbs. Chimeric viruses were constructed from 90-month-time-point PG9-sensitive AIIMS_329 and AIIMS_330 viruses with swapped V1V2 regions of their respective evolved viruses (at 112 and 117 months), which led to higher resistance to neutralization by PG9 and autologous plasma antibodies. We observed the evolution of a viral pool in the AIIMS_330 donor comprising plasma antibody neutralization-sensitive or -resistant diverse autologous viruses that may have contributed to the development and maintenance of elite neutralizing activity.IMPORTANCE Herein, we report the longitudinal development of bnAbs in a pair of chronically HIV-1 clade C-infected monozygotic pediatric twins, AIIMS_329 and AIIMS_330, who acquired the infection by vertical transmission. The plasma from both donors, sharing a similar genetic makeup and infecting virus, showed the evolvement of bnAbs targeting common epitopes in the V2 and V3 regions of the envelope, suggesting that bnAb development in these twins may perhaps be determined by specific sequences in the shared virus that can guide the development of immunogens aimed at eliciting V2 and V3 bNAbs. Characterization of the neutralization-sensitive and -resistant viruses coevolving with bNAbs in the contemporaneous AIIMS_330 plasma provides information toward understanding the viral alterations that may have contributed to the development of resistance to bnAbs. Further longitudinal studies in more monozygotic and dizygotic twin pairs will help in delineating the role of host and viral factors that may contribute to the development of bnAbs.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  envelope pseudoviruses; epitope mapping; monozygotic twins; pediatric elite neutralizers; plasma bnAbs

Mesh:

Substances:

Year:  2019        PMID: 31217240      PMCID: PMC6694815          DOI: 10.1128/JVI.00654-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India.

Authors:  Muzamil Ashraf Makhdoomi; Deepti Singh; Ambili Nair Pananghat; Rakesh Lodha; Sushil Kumar Kabra; Kalpana Luthra
Journal:  Virology       Date:  2016-09-17       Impact factor: 3.616

Review 3.  Paediatric HIV infection: the potential for cure.

Authors:  Philip J Goulder; Sharon R Lewin; Ellen M Leitman
Journal:  Nat Rev Immunol       Date:  2016-03-14       Impact factor: 53.106

4.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

5.  Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.

Authors:  Raiees Andrabi; James E Voss; Chi-Hui Liang; Bryan Briney; Laura E McCoy; Chung-Yi Wu; Chi-Huey Wong; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2015-11-17       Impact factor: 31.745

6.  Mutations in the reverse transcriptase and protease genes of human immunodeficiency virus-1 from antiretroviral naïve and treated pediatric patients.

Authors:  Dinesh Bure; Muzamil A Makhdoomi; Rakesh Lodha; Somi Sankaran Prakash; Rajesh Kumar; Hilal A Parray; Ravinder Singh; Sushil K Kabra; Kalpana Luthra
Journal:  Viruses       Date:  2015-02-10       Impact factor: 5.048

7.  Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.

Authors:  S Abigail Smith; Samantha L Burton; William Kilembe; Shabir Lakhi; Etienne Karita; Matt Price; Susan Allen; Eric Hunter; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2016-11-16       Impact factor: 6.823

8.  HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.

Authors:  Zanele Ditse; Maximilian Muenchhoff; Emily Adland; Pieter Jooste; Philip Goulder; Penny L Moore; Lynn Morris
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

9.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.

Authors:  Jinghe Huang; Gilad Ofek; Leo Laub; Mark K Louder; Nicole A Doria-Rose; Nancy S Longo; Hiromi Imamichi; Robert T Bailer; Bimal Chakrabarti; Shailendra K Sharma; S Munir Alam; Tao Wang; Yongping Yang; Baoshan Zhang; Stephen A Migueles; Richard Wyatt; Barton F Haynes; Peter D Kwong; John R Mascola; Mark Connors
Journal:  Nature       Date:  2012-09-18       Impact factor: 49.962

10.  HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms.

Authors:  Suprit Deshpande; Shilpa Patil; Rajesh Kumar; Tandile Hermanus; Kailapuri G Murugavel; Aylur K Srikrishnan; Suniti Solomon; Lynn Morris; Jayanta Bhattacharya
Journal:  Retrovirology       Date:  2016-08-30       Impact factor: 4.602

View more
  4 in total

1.  A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.

Authors:  Nitesh Mishra; Shaifali Sharma; Ayushman Dobhal; Sanjeev Kumar; Himanshi Chawla; Ravinder Singh; Bimal Kumar Das; Sushil Kumar Kabra; Rakesh Lodha; Kalpana Luthra
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

2.  Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins.

Authors:  Nitesh Mishra; Muzamil Ashraf Makhdoomi; Shaifali Sharma; Sanjeev Kumar; Ayushman Dobhal; Deepshikha Kumar; Himanshi Chawla; Ravinder Singh; Uma Kanga; Bimal Kumar Das; Rakesh Lodha; Sushil K Kabra; Kalpana Luthra
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

3.  Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence.

Authors:  Ria Goswami; Stella J Berendam; Shuk Hang Li; Ashley N Nelson; Kristina De Paris; Koen K A Van Rompay; Sallie R Permar; Genevieve G Fouda
Journal:  PLoS Pathog       Date:  2020-11-12       Impact factor: 6.823

4.  The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.

Authors:  Silvia Pérez-Yanes; María Pernas; Silvia Marfil; Romina Cabrera-Rodríguez; Raquel Ortiz; Víctor Urrea; Carla Rovirosa; Judith Estévez-Herrera; Isabel Olivares; Concepción Casado; Cecilio Lopez-Galindez; Julià Blanco; Agustín Valenzuela-Fernández
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.